0001520138-17-000167.txt : 20170509 0001520138-17-000167.hdr.sgml : 20170509 20170508210525 ACCESSION NUMBER: 0001520138-17-000167 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170509 DATE AS OF CHANGE: 20170508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55292 FILM NUMBER: 17824184 BUSINESS ADDRESS: STREET 1: 100 CUMMINGS CENTER, STREET 2: SUITE 247-C CITY: BEVERLY STATE: MA ZIP: 01915 BUSINESS PHONE: 312-283-5793 MAIL ADDRESS: STREET 1: 100 CUMMINGS CENTER, STREET 2: SUITE 247-C CITY: BEVERLY STATE: MA ZIP: 01915 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20170331_10q.htm FORM 10-Q FOR PERIOD ENDED MARCH 31, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2017

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 333-190635

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC)

(Exact name of registrant as specified in its charter)

Nevada		46-2510769
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

100 Cummings Center, Suite 247-C

Beverly, MA 01915

(Address of principal executive offices, Zip Code)

(312)-283-5793

(Registrant's telephone number, including area code)

NANOANTIBIOTICS, INC.

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

(Do not check if a smaller reporting company)

☐

Smaller reporting company

☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares outstanding of each of the issuer's classes of common equity, as of March 31, 2017 was 91,685,000.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)	2
	Balance Sheets as of March 31, 2017 (unaudited) and June 30, 2016 (audited)	2
	Statements of Operations (unaudited) for the three and nine months ended March 31, 2017 and 2016	3
	Statement of Changes in Shareholders’ Equity for the period to March 31, 2017	4
	Statements of Cash Flows (unaudited) for the nine months ended March 31, 2017 and 2016	5
	Notes to Financial Statements (unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition of and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 4.	Controls and Procedures	22

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3.	Defaults Upon Senior Securities	23
Item 4.	Mine Safety Disclosures	23
Item 5.	Other Information	23
Item 6.	Exhibits	23

SIGNATURES		24

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie, Inc.

-1-

Table of Contents

Part 1. Financial Information

Item 1. Financial Statements

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

BALANCE SHEETS

	March 31,			June 30,
	2017			2016
ASSETS	(unaudited)			(audited)

CURRENT ASSETS:
Cash		35,309			123,757
Prepaid expenses		—			6,982
Total Current Assets		35,309			130,739

OTHER ASSETS:
Intangible Assets (Net of Amortization)		2,070,701			2,242,734
Goodwill		345,711			345,711
Total Other Assets		2,416,413			2,588,445

TOTAL ASSETS		2,451,722			2,719,184

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES:
Accounts Payable and accrued expenses		330,118			293,633
Related Party Loan		10,000			10,000
Accrued Payroll		62,500			499,612
Total Current Liabilities		402,618			803,245

LONG TERM LIABILITIES:
Other Long Term Liabilities		575,917			—
Total Long Term Liabilities		575,917			—

STOCKHOLDERS' EQUITY (DEFICIT)

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $0.0001 par value; 300,000,000 shares authorized; shares issued and 91,685,000 and 87,160,001 shares issued and outstanding, respectively		9,168			8,716
Additional paid in capital		3,365,991			2,911,559
Receivable on account of shares issued		(10,000	)
Accumulated deficit		(1,891,973	)		(1,004,336	)
Total Stockholders' Equity (Deficit)		1,473,187			1,915,939

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		2,451,722			2,719,184

See accompanying notes to financial statement

-2-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

STATEMENT OF OPERATIONS (UNAUDITED)

	For the Three Months			For the Three Months			For the Nine Months			For the Nine Months
	Ended			Ended			Ended			Ended
	March 31,			March 31,			March 31,			March 31,
	2017			2016			2017			2016
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
REVENUE:
Sales	$	—		$	—			—			—

COST OF GOODS SOLD		—			—			—			—

GROSS MARGIN		—			—			—			—

OPERATING EXPENSES
Amortization		57,344			—			172,033			—
Research and development expenses		120,043			—			375,872			—
Payroll expenses		71,348			40,369			214,044			121,107
Professional fees		126,098			14,949			312,277			32,966
Selling, general and administrative expenses		25,693			2,536			35,453			8,336
TOTAL OPERATING EXPENSES		400,527			57,854			1,109,680			162,409

LOSS FROM OPERATIONS		(400,527	)		(57,854	)		(1,109,680	)		(162,409	)

OTHER EXPENSE (INCOME)
Other Income		(222,028	)		—			(222,028	)		—
Interest expense		—			—			—			—
Interest income		(3	)		(44	)		(14	)		(155	)
TOTAL OTHER EXPENSE (INCOME)		(222,031	)		(44	)		(222,042	)		(155	)

NET LOSS	$	(178,495	)	$	(57,810	)		(887,637	)		(162,254	)

NET LOSS PER COMMON SHARE, BASIC AND DILUTED	$	(0.00	)	$	(0.00	)		(0.01	)		(0.00	)

WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING, BASIC AND DILUTED		91,493,146			87,210,000			88,591,685			87,210,000

See accompanying notes to financial statement

-3-

Table of Contents

BIOVIE INC. (/K/A NANOANTIBIOTICS, INC.)

STATEMENT OF STOCKHOLDERS’ EQUITY

									Receivable on			Prepaid
							Additional		Account of			Services						Total
	Common Stock			Common Stock			Paid in		Shares			Paid with			Accumulated			Stockholders'
	Shares			Amount			Capital		Issued			Common Sock			Deficit			Deficit

Balance, June 30, 2014		87,210,000			8,721			514,485		—			(12,411	)		(339,406	)		171,389

Amortization of Prepaid services paid with common stock		—			—			—		—			7,500			—			7,500

Net loss		—			—			—		—			—			(233,008	)		(233,008	)

Balance, June 30, 2015		87,210,000			8,721			514,485		—			(4,911	)		(572,414	)		(54,119	)

Retirement of Shares		(39,869,999	)		(5	)		—		—			—			—			(5	)

Shares Issued for Acquisition		39,820,000			—			2,397,075		—			—			—			2,397,075

Prepaid services paid with common stock		—			—			—		—			4,911			—			4,911

Net loss		—			—			—		—			—			(431,923	)		(431,923	)

Balance, June 30, 2016		87,160,001			8,716			2,911,560		—			—			(1,004,337	)		1,915,939

Options vested (unaudited)		—			—			34,884		—			—			—			34,884

Issuance of Shares (unaudited)		4,524,999			452			419,547		(10,000	)		—			—			409,999

Net loss (unaudited)		—			—			—		—			—			(887,637	)		(887,637	)

Balance, March 31, 2017 (unaudited)		91,685,000			9,168			3,365,991		(10,000	)		—			(1,891,974	)		1,473,186

See accompanying notes to financial statement

-4-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

STATEMENT OF CASH FLOWS (UNAUDITED)

	For the Nine Months			For the Nine Months
	Ended			Ended
	March 31,			March 31,
	2017			2016
	(Unaudited)			(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(887,637	)	$	(162,254	)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Amortization of prepaid services paid with common stock					4,911
Amortization of intangible assets		172,033
Share based compensation expense		34,884
Changes in operating assets and liabilities
Decrease in prepaid expenses		6,982			2,000
Increase (decrease) in:
Receivables		—			—
Accounts Payable		209,818			—
Accrued Payroll		(34,526	)		121,106
Net cash used by operating activities		(498,447	)		(34,237	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used by investing activities		—			—

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from long term Liabilities		—			—
Proceeds from issuance of common Stock		409,999
Net cash provided by financing activities		409,999			—

Net decrease in cash		(88,448	)		(34,237	)

Cash, beginning of period		123,757			267,481

Cash, end of period	$	35,309		$	233,244

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	—		$	—
Cash paid for income tax	$	—		$	—

NON-CASH FINANCING ACTIVITIES
Gain on extinguishment of debt	$	222,028		$	—

See accompanying notes to financial statement

-5-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

1. Background Information

BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, BioVie received notification from the FDA that it could initiate a Phase 2a US clinical trial and in April the Company signed a Cooperative Research and Development Agreement (CRADA) with the McGuire Research Institute/VA in Richmond, VA, to begin dosing patients with BIV201 in mid-2017.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. It has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. For more information about BioVie and BIV201, please visit our website: www.biovieinc.com.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. We currently own all development and marketing rights to our drug candidate, except as noted previously, the Company and PharmaIN have exchanged small (low single-digit) ownership rights to each other’s ascites drug development programs. The Company recently filed patent applications for its drug candidate in the US and Japan, as well as a PCT in Europe. We are currently completing the work necessary to file our investigational new drug (IND) application, and aim to commence clinical trials should the FDA approve our application.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company’s business plan.

2. Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended March 31, 2017, the Company had a net loss of $887,637. As of March 31, 2017, the Company has not earned any revenues. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to begin operations and to achieve a level of profitability. Since inception, the Company has financed its activities principally from the sale of public equity securities. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes and proceeds from sub-licensing agreements until such time that funds provided by operations are sufficient to fund working capital requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

-6-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

3. Significant Accounting Policies

Unaudited Interim Financial Statements

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.

Basis of Presentation

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash

Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our cash balances were fully insured at March 31, 2017.

Financial Instruments

The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.

The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Research and Development

Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $375,872 for research and development for the nine months ended March 31, 2017.

-7-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

3. Significant Accounting Policies (continued)

Income Taxes

Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.

The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at March 31, 2017 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

Earnings (Loss) per Share

Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the period. For the three and nine months ended March 31, 2017 and 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.

Stock-based Compensation

The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

-8-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

3. Significant Accounting Policies (continued)

Fair Value Measurements

In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2017. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.

The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Recent accounting pronouncements

The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.

-9-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

4. Related Party Loan

LAT Pharma was given a zero-interest bearing loan by the company’s General Partner, Jonathan Adams in the amount of $5,000 in August 2015 and $5,000 in November 2015. The total of $10,000 was outstanding when the Company merged with LAT Pharma. As of March 31, 2017 the Company has an outstanding balance of $10,000 payable on demand to the CEO, Jonathan Adams.

On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of $180,555 until December 31, 2019, through the issuance of a Promissory note. The promissory note does not carry any interest charge as long as the amount is paid in full before December 31, 2019. The salary debt has thereby been reclassified from a current liability to a long term liability on the balance sheet.

On March 23, 2017, Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.25. The adjusted salary debt is $222,028.13. Elliot Ehrlich also agreed to defer the payment of his salary debt of $222,028.13 until December 31, 2019, through the issuance of a Promissory note. The promissory note does not carry any interest charge as long as the amount is paid in full before December 31, 2019. The salary debt has thereby been reclassified from a current liability to a long term liability on the balance sheet and the salary debt forgiven has been reflected on the income statement as other income.

5. Commitments and Contingencies

Office Lease

On January 1, 2014 the Company executed a lease agreement with Cummings Properties for the company’s office of 270 square feet at 100 Cummings Center, Suite 247-C, Beverly, MA 01915. The lease is for a term of five years from January 1, 2014 to December 30, 2018 and requires monthly payments of $369 ($4,428 annually for each of the five years, total aggregate of $22,140).

Employment Agreements

On April 11, 2016 the Company entered into employment agreement with CEO Jonathan Adams. The Company’s agreement provides for a three-year term with minimum annual base salary of $250,000 per year. Effective April 11, 2016, the (previous) CEO/CFO resigned.

-10-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

6. Income Taxes

Deferred taxes are recorded for all existing temporary differences in the Company’s assets and liabilities for income tax and financial reporting purposes. Due to the valuation allowance for deferred tax assets, as noted below, there were no net deferred tax benefit or expense for the nine months ended March 31, 2017.

There is no current or deferred income tax expense or benefit allocated to continuing operations for the nine months ended March 31, 2017.

The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference are as follows:

	March 31, 2017			June 30, 2016
Tax expense (benefit) at U.S. statutory rate	$	(301,797	)	$	(146,889	)
State income tax expense (benefit), net of federal benefit		(44,382	)		(21,659	)
Effect of non-deductible expenses
Other
Change in valuation allowance		346,179			168,548
	$	—		$	—

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at March 31, 2017 were as follows:

Deferred tax assets (liability), noncurrent:
Net operating loss	$	346,179
Valuation allowance		(346,179	)
	$	—

Change in valuation allowance:

Balance, June 30, 2016	$	391,848
Increase in valuation allowance		346,179
Balance, March 31, 2017		738,027

Since management of the Company believes that it is more likely than not that the net deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net deferred tax assets as of March 31, 2017.

As of March 31, 2017, the Company had federal and state net operating loss carry-forwards totaling approximately $1,870,000 which begin expiring in 2022.

-11-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

7. Purchase of LAT Pharma

On April 11, 2016, the Company entered into and consummated an Agreement and Plan of Merger (the “Merger Agreement”), with LAT Acquisition Corp., a Nevada corporation and wholly-owned subsidiary of the Company (“Acquisition”) and LAT Pharma, LLC an Illinois limited liability company (“LAT”). Pursuant to the terms of the Merger Agreement, Acquisition merged with and into LAT in a statutory triangular merger (the “Merger”) with LAT surviving as a wholly-owned subsidiary of the Company. As consideration for the Merger, the Company issued the interest holders of LAT (the “LAT Holders”) an aggregate of 39,820,000 shares of our Common Stock issued to the LAT Holders in accordance with their pro rata ownership of LAT membership interests prior to the Merger. Following the Merger, the Registrant will continue the development of LAT’s lead clinical therapeutic candidate Continuous low-dose Infusion (CI) Terlipressin.

Immediately prior to the Merger, the Company had 87,210,000 shares of Common Stock issued and outstanding. In connection with the Merger, certain shareholders of the Company collectively agreed to retire and cancel an aggregate of 39,869,999 shares of Common Stock. Following the consummation of the Merger, the issuance of the Merger Shares of the 39,820,000 shares of Common Stock, the Company had 87,160,001 shares of Common Stock issued and outstanding and the LAT Holders beneficially own 39,820,000 shares or approximately forty-six percent (46%) of such issued and outstanding Common Stock.

Under the purchase method of accounting, the transaction was valued for accounting purposes at $2,389,200, which was the estimated fair value of the consideration paid by the Company. The estimate was based on the consideration paid of 39,820,000 shares of common stock valued based on the closing price on 04/11/2016 of $0.06 per share.

The assets and liabilities of LAT Pharma, Inc. were recorded at their respective fair values as of the closing date of the Merger Agreement, and the following table summarizes these values based on the balance sheet at April 11, 2016.

$	2,303,682	Assets Purchased
	260,193	Liabilities Assumed
	2,043,489	Net Assets Purchased
	2,389,200	Purchase Price
$	345,711	Goodwill from Purchase

Intangible asset detail

$	2,293,770	Intangible Intellectual Property
	345,711	Goodwill
	2,639,481	Intangible Asset from Purchase

-12-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

7. Purchase of LAT Pharma(continued)

Under the 338(h)(10) election, intangibles and goodwill related to the acquisition of LAT Pharma will be fully deductible for tax purposes.

The intangible intellectual property is amortized over 10 years.

	March 2017		December 2015
Intangible Assets subject to Amortization	$	2,293,770	$	—
Amortization Expense for 9 Months	$	172,033	$	—
Accumulated Amortization as of March 31, 2017	$	280,413	$	—

The previous year amortization expense has been amortized for the period from April 11, 2016 to June 30, 2016. The estimated Amortization expense for each of the five succeeding fiscal years will be approximately $229,300 per year.

8. Stockholders’ Equity

Offering of Stock Options

In connection with the employment agreement signed with the Chief Financial Officer on April 11, 2016, Jonathan Adams received options to acquire 3 million shares exercisable at $0.06 per share, the closing price on that date. These Options Group A shall become vested and exercisable (i) as to 1 million shares on April 11, 2017, (ii) as to 1 million shares on April 11, 2018, and (iii) as to 1 million shares on April 11, 2019.

The fair market value of the stock options is estimated using the Black Scholes valuation model and the Company uses the following methods to determine its underlying assumptions: expected volatilities are based on the historical volatilities of 3 comparable companies of the daily closing price of their respective common stock; the expected term of options granted is based on the average time outstanding method; and the risk free interest rate is based on the US Treasury bonds issued with similar life terms to the expected life of the grant.

-13-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

8. Stockholders’ Equity(continued)

The following key assumptions were used in the valuation model to value stock option grants for each respective period:

Valuation Date	4/11/2016			4/11/2016			4/11/2016
Stock Price	$	0.06		$	0.06		$	0.06
Exercise Price	$	0.06		$	0.06		$	0.06
Term (expected term for options)		1.00			2.00			3.00
Volatility		56.49	%		58.45	%		97.82	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		0.53	%		0.70	%		0.85	%
Call Option Value ($Millions)	$	0.01		$	0.02		$	0.04
Fair Value	$	13,467		$	19,523		$	36,489

The Company issued stock options to consultants and board of directors for services provided to the company. The following key assumptions were used in the valuation model to value stock option grants for each respective period:

Valuation Date	11/16/2016			12/18/2016			03/14/17
Stock Price	$	0.25		$	0.21		$	0.22
Exercise Price	$	0.25		$	0.21		$	0.22
Term (expected term for options)		2.00			2.00			2.00
Volatility		43.12	%		43.12	%		40.02	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		1.02	%		1.15	%		1.40	%
Call Option Value ($Millions)	$	0.06		$	0.05		$	0.05
Fair Value	$	30,919		$	15,646		$	5,143

-14-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

8. Stockholders’ Equity(continued)

Stock option transactions under the Company’s plans for the years ended March 31, 2017 is summarized below:

			Weighted
		Weighed-	Average	Aggregate
		Average	Remaining	Intrinsic
	Shares	Exercise	Contractual	Value
Options	(Thousands)	Price	Term	(Thousands)
Outstanding at June 30, 2016	3,000	0.06	2	-
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at September 30, 2016	3,000	0.06	2	-
Granted	800	0.24	2	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at December 31, 2016	3,800	0.10	2	-
Granted	100	0.22	2	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at March 31, 2017	3,900	0.10	2	-

The compensation expense for the 9 months ended March 31, 2017 includes $26,544 related to the stock options described above. The Legal and Professional fee for the 9 months ended March 31, 2017 includes $8,340 related to the stock options described above.

Offerings of Common Stock and Warrants

In September 2016, the Company sold and issued an aggregate of 49,999 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $5,000. The purchase price for the common stock was $0.10 per share.

In October 2016, the Company sold and issued an aggregate of 225,000 shares of common stock and warrants to purchase 112,500 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $45,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.

In November 2016, the Company sold and issued an aggregate of 250,000 shares of common stock and warrants to purchase 125,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $50,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.

-15-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

8. Stockholders’ Equity(continued)

In January 2017, the Company sold and issued an aggregate of 100,000 shares of common stock and warrants to purchase 50,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $20,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.

In January 2017, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”) which provides that, on the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $12.0 million of shares of the Company’s common stock over the 30-month term of the Purchase Agreement. On execution of the Purchase Agreement, the Company agreed to sell to Aspire Capital 1,000,000 shares of common stock and warrants to purchase 500,000 shares of common stock for proceeds of $200,000. The Warrant Shares will each have a five-year term and will be exercisable at $0.50 per share. Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the “Registration Rights Agreement”), in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended (the “Securities Act”), registering the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the Purchase Agreement.

Under the Purchase agreement, after the Securities and Exchange Commission (the “SEC”) has declared effective the registration statement referred to above, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day, up to $12.0 million of the Company’s common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of:

the lowest sale price of the Company’s common stock on the purchase date; or
the arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date.

In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to 100,000 shares and the closing sale price of our stock is equal to or greater than $0.30 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company’s common stock traded on its principal market on the VWAP Purchase Date.

-16-

Table of Contents

BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.)

Notes to Financial Statements

For the Three and Nine Months Ended March 31, 2017 and 2016

(unaudited)

8. Stockholders’ Equity(continued)

The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed.

The Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where the closing sale price of the Company’s common stock is less than $0.10. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of sales of the Company’s common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 2,400,000 shares of the Company’s common stock (the “Commitment Shares”). The Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the Purchase Agreement. Any proceeds that the Company receives under the Purchase Agreement are expected to be used for working capital and general corporate purposes.

In March 2017, the Company sold and issued an aggregate of 500,000 shares of common stock and warrants to purchase 250,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $100,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.

9. Renegotiated Debt

On March 23, 2017, Barrett Ehrlich agreed to defer the payment of his consulting fee debt of $173,333.33 until December 31, 2019, through the issuance of a Promissory note. The promissory note does not carry any interest charge as long as the amount is paid in full before December 31, 2019. The consulting fee debt has thereby been reclassified from a current liability to a long term liability on the balance sheet.

On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of $180,555.64 until December 31, 2019, through the issuance of a Promissory note. The promissory note does not carry any interest charge as long as the amount is paid in full before December 31, 2019. The salary debt has thereby been reclassified from a current liability to a long term liability on the balance sheet.

-17-

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

-18-

Table of Contents

We are a development stage biotechnology company engaged in the discovery, development and commercialization of a therapy targeting ascites due to liver cirrhosis. Ascites due to liver cirrhosis is a life-threatening condition affecting about 100,000 Americans and many times more worldwide. Our therapy BIV201 is based on a drug that is approved in about 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients. We are currently completing the work necessary to file our investigational new drug (IND) application, and aim to commence clinical trials should the FDA approve our application. The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company’s business plan.

We have incurred $400,527 of operating expenses for the quarter ended March 31, 2017. We are now engaged in organizational activities and sourcing compounds and materials. We anticipate incurring other costs associated with equipment purchases and general and administrative expenses, including employee salaries and benefits, legal expenses, and other costs associated with an early stage, publicly-traded company.

The amounts that we actually spend for any specific purpose may vary significantly, and will depend on a number of factors including, but not limited to, the pace of progress of our research and development, market conditions, and our ability to qualify vendors. In addition, we may use a portion of any net proceeds to acquire complementary compounds; however, we do not have plans for any acquisitions at this time. We will have significant discretion in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of our Common Stock.

Requirement for Additional Capital

The Company has engaged in research and development activities. Assuming that we are successful in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:

●	Research and Development of $600,000 which includes planned near-term costs for the development of BIV201.
●	Corporate overhead of $200,000 which includes budgeted legal, accounting and other costs expected to be incurred; and
●	Staffing costs of $250,000

The Company had approximately $35,309 of cash on hand at March 31, 2017 and will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital costs, or staffing costs without obtaining additional net financing of approximately $500,000 to $1,000,000 to meet its near-term budgetary needs.

The actual work to be performed can only be broadly projected, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development.

-19-

Table of Contents

Management intends to use capital and debt financing, as required, to fund the Company's operations. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to fund its anticipated obligations for the next twelve (12) months.

Capital Resources and Liquidity

As of March 31, 2017, we had $35,309 of cash on hand in our corporate bank account. The Company is considered to be a development stage company and will continue in the development stage until generating revenues from the sales of its products or services. As a result, the report of the independent registered public accounting firm on our financial statements as of June 30, 2016, contains an explanatory paragraph regarding a substantial doubt about our ability to continue as a going concern.

Currently we do not have sufficient funds for the next (12) twelve months and must raise cash to implement our strategy. If we are unable to raise additional funds to develop our compounds, we may be required to scale back our development plans by reducing expenditures for employees, consultants, business development, and other envisioned expenditures. This could reduce our ability to develop BIV201, our drug candidate, and implement our business plan. In that event, investors should anticipate that their entire investment may be lost and there may be no ability to profit from this investment.

We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

If we are unable to raise additional funds, we will need to do one or more of the following

	· delay, scale-back or eliminate some or all of our research and product development programs;
	· provide licenses to third parties to develop and commercialize products or technologies that we would otherwise seek to develop and commercialize ourselves;
	· seek strategic alliances or business combinations;
	· attempt to sell our company;
	· cease operations; or
	· declare bankruptcy.

The above conditions raise doubt about our ability to continue as a going concern. The financial statements included elsewhere herein were prepared under the assumption that we would continue our operations as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. Without additional funds from debt or equity financing, sales of our intellectual property or technologies, or from a business combination or a similar transaction, we will soon exhaust our resources and will be unable to continue operations. If we cannot continue as a viable entity, our stockholders may lose some or all of their investment in BioVie.

-20-

Table of Contents

Our management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

Emerging Growth Company

We are an “emerging growth company” under the federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Results of Operations

Research and Development

Research and development expenses were $120,043 for the three months ended March 31, 2017, and were $375,872 for the nine months ended March 31, 2017. For the prior year, the Company did not have any research and development expenses. The research and development expenses were primarily due to the expenses incurred for clinical development activities.

Selling, General and Administrative

Selling, general and administrative expenses were $25,693 for the three months ended March 31, 2017, an increase of $23,157 compared to $2,536 for the three months ended March 31, 2016. Selling, general and administrative expenses were $35,453 for the nine months ended March 31, 2017, an increase of $27,117, compared to $8,336 for the nine months ended March 31, 2016. The increase over the prior year was primarily due to travel and conference expenses associated with financing activities.

-21-

Table of Contents

Professional Fees

Professional fees were $126,098 for the three months ended March 31, 2017, an increase of $111,149, compared to $14,949 for the three months ended March 31, 2016. Professional fees were $312,277 for the nine months ended March 31, 2017, an increase of $279,311, compared to $32,966 for the nine months ended March 31, 2016. The increase in professional fees related to increased costs for commercialization activities, intellectual property management, general legal and financial expenses.

Payroll Expenses

Payroll expenses were $71,348 for the three months ended March 31, 2017, an increase of $30,979, compared to $40,369 for the three months ended March 31, 2016. Payroll expenses were $214,044 for the nine months ended March 31, 2017, an increase of $92,937, compared to $121,107 for the nine months ended March 31, 2016. The increase in payroll expense was primarily due to an increase in accrued salary for the new chief executive officer, Jonathan Adams who joined the Company in April 2016.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

Item 4. Controls and Procedures

The Company’s Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2017 covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act. This conclusion by the Company’s Chief Executive Officer and Chief Financial Officer does not relate to reporting periods after March 31, 2017.

Changes in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting occurred during the quarter ended March 31, 2017, that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

-22-

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

Item 2. Unregistered sales of equity securities

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

Item 6. Exhibits

(a) Exhibit index

Exhibit

31.1		Certification of Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

(b) Reports on Form 8-K

None.

-23-

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIOVIE, INC.


Signature	Titles	Date
/s/ Jonathan Adams
Jonathan Adams	Chief Executive Officer, Chief Financial Officer, Principal Executive Officer, Principal Accounting Officer	May 8, 2017

-24-

EX-31.1 2 bivi-20170331_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Jonathan Adams, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Biovie, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 3 bivi-20170331_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Biovie, Inc., (the “Company”) on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan Adams, Chief Executive Officer, Chief Financial Officer, Principal Executive Officer and Principal Financial and Accounting Officer, Corporate Secretary, Treasurer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.LAB 4 bivi-20170331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Shares Capital in Excess of Par Value Accumulated Deficit Prepaid Services Paid with Common Sock Common Stock Subsequent Event Type [Axis] LAT Pharma, Inc. [Member] Derivative Instrument [Axis] Stock Option [Member] Stock Option [Member] Stock Option [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Prepaid expenses Total Current Assets OTHER ASSETS: Intangible Assets (Net of Amortization) Goodwill Total Fixed Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts Payable and accrued expenses Related Party Loan Accrued Payroll Total Current Liabilities LONG TERM LIABILITIES: Other Long Term Liabilities Total Long Term Liabilities STOCKHOLDERS' EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 300,000,000 shares authorized; shares issued and 91,685,000 and 87,160,001 shares issued and outstanding, respectively Additional paid in capital Receivable on account of shares issued Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock Shares Issued Common stock, shares outstanding Income Statement [Abstract] REVENUE: Sales COST OF GOODS SOLD GROSS MARGIN OPERATING EXPENSES Amortization Research and development expenses Payroll expenses Professional fees Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Other Income Interest Expense Interest income TOTAL OTHER EXPENSE (INCOME) NET LOSS NET LOSS PER COMMON SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance (in shares) Retirement of Shares Retirement of Shares (in shares) Option vested Shares Issued for Acquisition Shares Issued for Acquisition (in shares) Issuance of common stock for services Issuance of common stock for services, (in shares) Amortization of prepaid services paid with common stock Net Loss Ending Balance Ending Balance (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash to cash used by operating activities: Amortization of prepaid common stock for services Amortization of intangible assets Share based compensation expense Changes in operating assets and liabilities: Increase in prepaid expenses Receivables Accounts Payable Accrued Payroll Net cash used by operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Net cash used by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from loan payable Proceeds from issuance of common stock Net cash provided by financing activities Net decrease in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for Income Tax NON-CASH FINANCING ACTIVITIES Gain on extinguishment of debt Notes to Financial Statements Background Information Going Concern Accounting Policies [Abstract] Significant Accounting Policies Related Party Transactions [Abstract] Related Party Loan Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Income Tax Disclosure [Abstract] Income Taxes Business Combinations [Abstract] Purchase of LAT Pharma Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockholders' Equity Renegotiated Debt Unaudited Interim Financial Statements Basis of Presentation Cash Financial Instruments Research and Development Income Taxes Earnings (Loss) per Share Stock-based Compensation Fair Value Measurements Recent accounting pronouncements Reconciliation of the federal statutory income tax rate to income tax expense expense Schedule of gross amounts of deferred tax assets and deferred tax liabilities Purchase Of Lat Pharma Tables Schedule of Assets and Liabilities of LAT Pharma, Inc. Stockholders Equity Tables Schedule of Stock option grants for each respective period Net Loss Lease rental Lease term (in years) Tax expense (benefit) at U.S. statutory rate State income tax expense (benefit), net of federal benefit Effect of non-deductible expenses Other Change in valuation allowance Total Income Taxes Details 2 Deferred tax assets (liability) Net operating loss Valuation allowance Total Federal and State net operating loss carry-forwards Change in valuation allowance: Beginning Balance Increase in valuation allowance Ending Balance Business Acquisition [Axis] Assets Purchased Liabilities Assumed Net Assets Purchased Purchase Price Intangible Intellectual Property Intangible Asset from Purchase Purchase Of Lat Pharma Details 2 Intangible Assets subject to Amortization Amortization Expense Accumulated Amortization Stockholders Equity Details Option Outstanding at beginning of year Option Granted Option Exercised Option Forfeited Option Outstanding at end of year Outstanding Weighted Average Exercise Price at the beginning Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Forfeited Outstanding Weighted Average Exercise Price at the end Weighted Average Remaining Contractual Term (in years) EX-101.PRE 5 bivi-20170331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 6 bivi-20170331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATION link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Related Party Loan link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Purchase of LAT Pharma link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Renegotiated Debt link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Purchase of LAT Pharma (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income Taxes (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Taxes (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Purchase of LAT Pharma (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Purchase of LAT Pharma (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stockholders' Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink EX-101.INS 7 bivi-20170331.xml XBRL INSTANCE FILE 0001580149 2016-06-30 0001580149 2017-03-31 0001580149 us-gaap:CommonStockMember 2014-06-30 0001580149 us-gaap:CommonStockMember 2015-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0001580149 us-gaap:RetainedEarningsMember 2014-06-30 0001580149 us-gaap:RetainedEarningsMember 2015-06-30 0001580149 bivi:PrepaidServicesPaidWithCommonStockMember 2015-06-30 0001580149 bivi:PrepaidServicesPaidWithCommonStockMember 2014-06-30 0001580149 2017-01-01 2017-03-31 0001580149 us-gaap:RetainedEarningsMember 2014-07-01 2015-06-30 0001580149 us-gaap:CommonStockMember 2014-07-01 2015-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2014-07-01 2015-06-30 0001580149 bivi:PrepaidServicesPaidWithCommonStockMember 2014-07-01 2015-06-30 0001580149 2017-03-01 2017-03-31 0001580149 2015-04-01 2016-03-31 0001580149 2014-04-01 2019-03-31 0001580149 2014-06-30 0001580149 us-gaap:CommonStockMember 2015-07-01 2016-06-30 0001580149 us-gaap:CommonStockMember 2016-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2015-07-01 2016-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0001580149 bivi:PrepaidServicesPaidWithCommonStockMember 2015-07-01 2016-06-30 0001580149 bivi:PrepaidServicesPaidWithCommonStockMember 2016-06-30 0001580149 us-gaap:RetainedEarningsMember 2015-07-01 2016-06-30 0001580149 us-gaap:RetainedEarningsMember 2016-06-30 0001580149 2015-07-01 2016-03-31 0001580149 bivi:LATPharmaIncMember 2016-04-11 0001580149 2016-07-01 2017-03-31 0001580149 2016-12-31 0001580149 2016-01-01 2016-03-31 0001580149 us-gaap:CommonStockMember 2016-07-01 2017-03-31 0001580149 us-gaap:CommonStockMember 2017-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-03-31 0001580149 us-gaap:RetainedEarningsMember 2016-07-01 2017-03-31 0001580149 us-gaap:RetainedEarningsMember 2017-03-31 0001580149 2014-07-01 2015-06-30 0001580149 2015-07-01 2016-06-30 0001580149 2015-06-30 0001580149 2016-03-31 0001580149 2016-07-01 2016-09-30 0001580149 2016-10-01 2016-12-31 0001580149 2016-09-30 0001580149 bivi:StockOptionOneMember 2016-04-11 0001580149 bivi:StockOptionOneMember 2016-04-10 2016-04-11 0001580149 bivi:StockOptionTwoMember 2016-04-11 0001580149 bivi:StockOptionTwoMember 2016-04-10 2016-04-11 0001580149 us-gaap:StockOptionMember 2016-04-10 2016-04-11 0001580149 us-gaap:StockOptionMember 2016-04-11 0001580149 us-gaap:StockOptionMember 2016-11-16 0001580149 us-gaap:StockOptionMember 2016-11-15 2016-11-16 0001580149 us-gaap:StockOptionMember 2016-12-17 2016-12-18 0001580149 us-gaap:StockOptionMember 2016-12-18 0001580149 us-gaap:StockOptionMember 2017-03-14 0001580149 us-gaap:StockOptionMember 2017-03-13 2017-03-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

130739

35309

2719184

2451722

293633

330118

803245

402618

2911559

3365991

1915939

1473186

8721

514485

-339406

-572414

-4911

-12411

171389

8716

2911560

-1004337

9168

3365991

-1891974

-54119

2719184

2451722

10000000

300000000

87160000

91685000

87210000

87160001

91685000

-178495

-233008

-431923

-162254

-887637

-57810

-887637

-233008

-431923

-34237

-498447

409999

8716

9168

0.001

87160000

91685000

209818

-34237

-88448

123757

35309

267481

233244

369

4284

21420

P5Y 4911

-301797

-146889

346179

168548

391848

738027

346179

-44382

-21659

0.0001

499612

62500

121106

-34526

6982

7500 4911 7500 4911

2000

6982

1870000

2303682

260193

2043489

2389200

-1004336

-1891973

2242734

2070701

345711

2588445

2416413

10000

-39869999 -5 -5

39820000

2397075

34884

2639481

2293710

2293770

57344

172033

120043

375872

71348

121107

214044

40369

126098

32966

312277

14949

25693

8336

35453

2536

400527

162409

1109680

57854

-400527

-162409

-1109680

-57854

155

222031

155

222042

-0.01

91493146

87210000

88591685

87210000

3000

3900

3800

3000

0.06

.10

0.06

.22

.24

P2Y

409999

34884 34884

4524999

409999

452

419547

91685000

100

800

BIOVIE INC. 0001580149 10-Q 2017-03-31 false --06-30 No No Yes Smaller Reporting Company Q3 2017 -10000

575917

-222028

222028

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">8.</td><td style="width: 5pt"></td><td style="text-align: justify">Stockholders’ Equity</td> </tr></table>   Offering of Stock Options   In connection with the employment agreement signed with the Chief Financial Officer on April 11, 2016, Jonathan Adams received options to acquire 3 million shares exercisable at $0.06 per share, the closing price on that date. These Options Group A shall become vested and exercisable (i) as to 1 million shares on April 11, 2017, (ii) as to 1 million shares on April 11, 2018, and (iii) as to 1 million shares on April 11, 2019.   The fair market value of the stock options is estimated using the Black Scholes valuation model and the Company uses the following methods to determine its underlying assumptions: expected volatilities are based on the historical volatilities of 3 comparable companies of the daily closing price of their respective common stock; the expected term of options granted is based on the average time outstanding method; and the risk free interest rate is based on the US Treasury bonds issued with similar life terms to the expected life of the grant.   The following key assumptions were used in the valuation model to value stock option grants for each respective period:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Valuation Date</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4/11/2016</td> <td colspan="3" style="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">4/11/2016</td> <td colspan="3" style="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">4/11/2016</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 55%; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Stock Price</td> <td style="width: 5%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 11%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="width: 1%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 11%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="width: 2%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 11%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="width: 1%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Term (expected term for options)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">1.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">2.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">3.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">56.49</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">58.45</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">97.82</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Annual Rate of Quarterly Dividends</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Discount Rate - Bond Equivalent Yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.53</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.70</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.85</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Call Option Value ($Millions)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.01</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.02</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.04</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">13,467</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">19,523</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">36,489</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>   The Company issued stock options to consultants and board of directors for services provided to the company. The following key assumptions were used in the valuation model to value stock option grants for each respective period:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Valuation Date</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">11/16/2016</td> <td colspan="3" style="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">12/18/2016</td> <td colspan="3" style="text-align: center; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">03/14/17</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 60%; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Stock Price</td> <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.25</td> <td style="width: 1%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.21</td> <td style="width: 2%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 10%; text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.22</td> <td style="width: 1%; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.25</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.21</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.22</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Term (expected term for options)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">2.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">2.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">2.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">43.12</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">43.12</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">40.02</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Annual Rate of Quarterly Dividends</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.00</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Discount Rate - Bond Equivalent Yield</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">1.02</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">1.15</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">1.40</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Call Option Value ($Millions)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.06</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.05</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">0.05</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">30,919</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">15,646</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">$</td> <td style="text-align: right; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">5,143</td> <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>   Stock option transactions under the Company’s plans for the years ended March 31, 2017 is summarized below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: white"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Weighed-</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Intrinsic</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Value</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="font-weight: bold; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Term</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Thousands)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; padding-bottom: 1pt">Outstanding at June 30, 2016</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">3,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">0.06</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">—  </td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Outstanding at September 30, 2016</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.24</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Outstanding at December 31, 2016</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">3,800</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Granted</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.22</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Outstanding at March 31, 2017</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">3,900</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">0.10</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   The compensation expense for the 9 months ended March 31, 2017 includes $26,544 related to the stock options described above. The Legal and Professional fee for the 9 months ended March 31, 2017 includes $8,340 related to the stock options described above.   Offerings of Common Stock and Warrants   In September 2016, the Company sold and issued an aggregate of 49,999 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $5,000. The purchase price for the common stock was $0.10 per share.   In October 2016, the Company sold and issued an aggregate of 225,000 shares of common stock and warrants to purchase 112,500 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $45,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.   In November 2016, the Company sold and issued an aggregate of 250,000 shares of common stock and warrants to purchase 125,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $50,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.   In January 2017, the Company sold and issued an aggregate of 100,000 shares of common stock and warrants to purchase 50,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $20,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.   In January 2017, the Company, entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”) which provides that, on the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $12.0 million of shares of the Company’s common stock over the 30-month term of the Purchase Agreement. On execution of the Purchase Agreement, the Company agreed to sell to Aspire Capital 1,000,000 shares of common stock and warrants to purchase 500,000 shares of common stock for proceeds of $200,000. The Warrant Shares will each have a five-year term and will be exercisable at $0.50 per share. Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital (the “Registration Rights Agreement”), in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended (the “Securities Act”), registering the sale of the shares of the Company’s common stock that have been and may be issued to Aspire Capital under the Purchase Agreement.   Under the Purchase agreement, after the Securities and Exchange Commission (the “SEC”) has declared effective the registration statement referred to above, on any trading day selected by the Company, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a “Purchase Notice”), directing Aspire Capital (as principal) to purchase up to 100,000 shares of the Company’s common stock per business day, up to $12.0 million of the Company’s common stock in the aggregate at a per share price (the “Purchase Price”) equal to the lesser of:   <ul style="margin-top: 0in; list-style-type: disc"> <li style="font: 10pt Times New Roman, Times, Serif; margin: 0px; text-align: justify">the lowest sale price of the Company’s common stock on the purchase date; or</li> <li style="font: 10pt Times New Roman, Times, Serif; margin: 0px; text-align: justify">the arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date.</li> </ul> In addition, on any date on which the Company submits a Purchase Notice to Aspire Capital in an amount equal to 100,000 shares and the closing sale price of our stock is equal to or greater than $0.30 per share, the Company also has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a “VWAP Purchase Notice”) directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on its principal market on the next trading day (the “VWAP Purchase Date”), subject to a maximum number of shares the Company may determine. The purchase price per share pursuant to such VWAP Purchase Notice is generally 95% of the volume-weighted average price for the Company’s common stock traded on its principal market on the VWAP Purchase Date.   The Purchase Price will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the Purchase Price. The Company may deliver multiple Purchase Notices and VWAP Purchase Notices to Aspire Capital from time to time during the term of the Purchase Agreement, so long as the most recent purchase has been completed.   The Purchase Agreement provides that the Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any purchase date where the closing sale price of the Company’s common stock is less than $0.10. There are no trading volume requirements or restrictions under the Purchase Agreement, and the Company will control the timing and amount of sales of the Company’s common stock to Aspire Capital. Aspire Capital has no right to require any sales by the Company, but is obligated to make purchases from the Company as directed by the Company in accordance with the Purchase Agreement. There are no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the Purchase Agreement. In consideration for entering into the Purchase Agreement, concurrently with the execution of the Purchase Agreement, the Company issued to Aspire Capital 2,400,000 shares of the Company’s common stock (the “Commitment Shares”). The Purchase Agreement may be terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital has agreed that neither it nor any of its agents, representatives and affiliates shall engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the Purchase Agreement. Any proceeds that the Company receives under the Purchase Agreement are expected to be used for working capital and general corporate purposes.   In March 2017, the Company sold and issued an aggregate of 500,000 shares of common stock and warrants to purchase 250,000 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately $100,000. The purchase price for the common stock and warrants was $0.20 per unit. The warrants are exercisable at an exercise price of $0.50 at any time from date of issuance until 5 years from the date of issuance.

Basis of Presentation   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash   Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our cash balances were fully insured at March 31, 2017.

Financial Instruments   The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.    The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Research and Development   Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $375,872 for research and development for the nine months ended March 31, 2017.

Income Taxes   Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.    The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at March 31, 2017 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

Earnings (Loss) per Share   Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the period. For the three and nine months ended March 31, 2017 and 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.

Stock-based Compensation   The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

Fair Value Measurements   In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:    Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.    Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.    Level 3 - Inputs that are both significant to the fair value measurement and unobservable.    Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2017. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll.   The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Recent accounting pronouncements   The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">March 31, 2017</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">June 30, 2016 </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-bottom: 1pt">Tax expense (benefit) at U.S. statutory rate</td><td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(301,797</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td><td style="width: 8%; padding-bottom: 1pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(146,889</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">State income tax expense (benefit), net of federal benefit</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">(44,382</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">(21,659</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Effect of non-deductible expenses</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">346,179</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">168,548</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at March 31, 2017 were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Deferred tax assets (liability), noncurrent:</td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Net operating loss</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">346,179</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(346,179</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Change in valuation allowance:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%">Balance, June 30, 2016</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">391,848</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Increase in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">346,179</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Balance, March 31, 2017</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">738,027</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,303,682</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 70%; text-align: justify">Assets Purchased</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">260,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Liabilities Assumed</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td style="text-align: right">2,043,489</td><td style="text-align: left"> </td><td> </td> <td style="text-align: justify">Net Assets Purchased</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,389,200</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Purchase Price</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">345,711</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt">Goodwill from Purchase</td></tr> </table>   Intangible asset detail    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 10%"> </td> <td style="width: 70%; text-align: justify">Intangible Intellectual Property</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">345,711</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: justify; padding-bottom: 1pt">Goodwill</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">2,639,481</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: justify; padding-bottom: 2.5pt">Intangible Asset from Purchase</td></tr> </table>

The following key assumptions were used in the valuation model to value stock option grants for each respective period: <table cellspacing="0" cellpadding="0" style="font-size: 11pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="line-height: 115%">Valuation Date</td> <td style="line-height: 115%"> </td> <td colspan="3" style="border: black 1pt solid; text-align: center; line-height: 115%">4/11/2016</td> <td colspan="3" style="text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">4/11/2016</td> <td colspan="3" style="text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">4/11/2016</td></tr> <tr style="vertical-align: bottom"> <td style="width: 55%; line-height: 115%; padding-left: 5.4pt">Stock Price</td> <td style="width: 5%; line-height: 115%"> </td> <td style="width: 1%; line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="width: 11%; text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="width: 1%; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="width: 1%; line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="width: 11%; text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="width: 2%; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="width: 1%; line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="width: 11%; text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="width: 1%; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Exercise Price</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.06</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Term (expected term for options)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">1.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">2.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">3.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Volatility</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">56.49</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">58.45</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">97.82</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Annual Rate of Quarterly Dividends</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Discount Rate - Bond Equivalent Yield</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.53</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.70</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.85</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Call Option Value ($Millions)</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.01</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.02</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">0.04</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 115%; padding-left: 5.4pt">Fair Value</td> <td style="line-height: 115%"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">13,467</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">19,523</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; border-bottom: black 1pt solid">36,489</td> <td style="line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> </table>   The Company issued stock options to consultants and board of directors for services provided to the company. The following key assumptions were used in the valuation model to value stock option grants for each respective period: <table cellspacing="0" cellpadding="0" style="font-size: 11pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr> <td style="line-height: 115%; vertical-align: bottom">Valuation Date</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td colspan="3" style="border: black 1pt solid; text-align: center; line-height: 115%; vertical-align: bottom">11/16/2016</td> <td colspan="3" style="text-align: center; line-height: 115%; vertical-align: bottom; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">12/18/2016</td> <td colspan="3" style="text-align: center; line-height: 115%; vertical-align: top; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid">03/14/17</td></tr> <tr> <td style="width: 60%; line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Stock Price</td> <td style="width: 3%; line-height: 115%; vertical-align: bottom"> </td> <td style="width: 1%; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="width: 10%; text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.25</td> <td style="width: 1%; line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="width: 1%; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">$</td> <td style="width: 10%; text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.21</td> <td style="width: 2%; line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="width: 1%; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">$</td> <td style="width: 10%; text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">0.22</td> <td style="width: 1%; line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Exercise Price</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.25</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.21</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">0.22</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Term (expected term for options)</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">2.00</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">2.00</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">2.00</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Volatility</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">43.12</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">43.12</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">40.02</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Annual Rate of Quarterly Dividends</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">0.00</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Discount Rate - Bond Equivalent Yield</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">1.02</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">1.15</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid"> </td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">1.40</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid">%</td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Call Option Value ($Millions)</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.06</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">0.05</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">0.05</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> <tr> <td style="line-height: 115%; padding-left: 5.4pt; vertical-align: bottom">Fair Value</td> <td style="line-height: 115%; vertical-align: bottom"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid; border-left: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">30,919</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: bottom; border-bottom: black 1pt solid">15,646</td> <td style="line-height: 115%; vertical-align: bottom; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td> <td style="line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">$</td> <td style="text-align: right; line-height: 115%; vertical-align: top; border-bottom: black 1pt solid">5,143</td> <td style="line-height: 115%; vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid"> </td></tr> </table>   Stock option transactions under the Company’s plans for the years ended March 31, 2017 is summarized below: <table cellspacing="0" cellpadding="0" style="font-size: 11pt; line-height: normal; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 40%; line-height: 115%"> </td> <td style="width: 15%; text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid"> </td> <td style="width: 15%; text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid"> </td> <td style="width: 15%; text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid">Weighted </td> <td style="width: 15%; text-align: center; line-height: 115%; border-top: black 1pt solid; border-right: black 1pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Weighed-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Average</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Aggregate</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-left: black 1pt solid"> </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Average</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Remaining</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Intrinsic </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%"> </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-left: black 1pt solid">Shares</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Exercise</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Contractual</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid">Value </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Options</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">(Thousands)</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">Price</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">Term</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">(Thousands)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at June 30, 2016</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">3,000</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.06</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercised </td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Forfeited</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at September 30, 2016</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">3,000</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.06</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">800</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.24</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercised</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Forfeited</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at December 31, 2016</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">3,800</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.10</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Granted</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">100</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.22</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Exercised</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Forfeited</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 115%">Outstanding at March 31, 2017</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">3,900</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">0.10</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">2</td> <td style="text-align: center; line-height: 115%; border-right: black 1pt solid; border-bottom: black 1pt solid">-</td></tr> </table>

280413

19523 36489 13467 30919 15646 5143 20000 40000 10000 60000 50000 50000

0.5845

0.9782

0.5649

0.4312

0.4002

P2Y

P3Y

P1Y

P2Y

0.06

0.25

0.21

0.22

0.06

0.25

0.21

0.22

0.007

0.0085

0.0053

0.0102

0.0115

0.014

EX-101.CAL 8 bivi-20170331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 bivi-20170331_def.xml XBRL DEFINITION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	9 Months Ended
Document and Entity Information	Mar. 31, 2017 shares
Document And Entity Information
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	91,685,000
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 11 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Mar. 31, 2017	Jun. 30, 2016
CURRENT ASSETS:
Cash	$ 35,309	$ 123,757
Prepaid expenses		6,982
Total Current Assets	35,309	130,739
OTHER ASSETS:
Intangible Assets (Net of Amortization)	2,070,701	2,242,734
Goodwill	345,711	345,711
Total Fixed Assets	2,416,413	2,588,445
TOTAL ASSETS	2,451,722	2,719,184
CURRENT LIABILITIES:
Accounts Payable and accrued expenses	330,118	293,633
Related Party Loan	10,000	10,000
Accrued Payroll	62,500	499,612
Total Current Liabilities	402,618	803,245
LONG TERM LIABILITIES:
Other Long Term Liabilities	575,917
Total Long Term Liabilities	575,917
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 300,000,000 shares authorized; shares issued and 91,685,000 and 87,160,001 shares issued and outstanding, respectively	9,168	8,716
Additional paid in capital	3,365,991	2,911,559
Receivable on account of shares issued	(10,000)
Accumulated deficit	(1,891,973)	(1,004,336)
Total Stockholders' Equity	1,473,186	1,915,939
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,451,722	$ 2,719,184

XML 12 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2017	Jun. 30, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common Stock Shares Issued	91,685,000	87,160,000
Common stock, shares outstanding	91,685,000	87,160,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATION - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATION - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
REVENUE:
Sales
COST OF GOODS SOLD
GROSS MARGIN
OPERATING EXPENSES
Amortization	57,344		172,033
Research and development expenses	120,043		375,872
Payroll expenses	71,348	40,369	214,044	121,107
Professional fees	126,098	14,949	312,277	32,966
Selling, general and administrative expenses	25,693	2,536	35,453	8,336
TOTAL OPERATING EXPENSES	400,527	57,854	1,109,680	162,409
LOSS FROM OPERATIONS	(400,527)	(57,854)	(1,109,680)	(162,409)
OTHER EXPENSE (INCOME)
Other Income	(222,028)		(222,028)
Interest Expense
Interest income	(3)	(44)	(14)	(155)
TOTAL OTHER EXPENSE (INCOME)	(222,031)	(44)	(222,042)	(155)
NET LOSS	$ (178,495)	$ (57,810)	$ (887,637)	$ (162,254)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED			$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	91,493,146	87,210,000	88,591,685	87,210,000

XML 14 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock Shares	Capital in Excess of Par Value	Prepaid Services Paid with Common Sock	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2014	$ 8,721	$ 514,485	$ (12,411)	$ (339,406)	$ 171,389
Beginning Balance (in shares) at Jun. 30, 2014	87,210,000
Retirement of Shares
Amortization of prepaid services paid with common stock			7,500		7,500
Net Loss				(233,008)	(233,008)
Ending Balance at Jun. 30, 2015	$ 8,721	514,485	(4,911)	(572,414)	(54,119)
Ending Balance (in shares) at Jun. 30, 2015	87,210,000
Retirement of Shares	$ (5)				(5)
Retirement of Shares (in shares)	(39,869,999)
Shares Issued for Acquisition		2,397,075			2,397,075
Shares Issued for Acquisition (in shares)	39,820,000
Amortization of prepaid services paid with common stock			4,911		4,911
Net Loss				(431,923)	(431,923)
Ending Balance at Jun. 30, 2016	$ 8,716	2,911,560		(1,004,337)	1,915,939
Ending Balance (in shares) at Jun. 30, 2016	87,160,001
Option vested		34,884			34,884
Issuance of common stock for services	$ 452	419,547			409,999
Issuance of common stock for services, (in shares)	4,524,999
Net Loss				(887,637)	(887,637)
Ending Balance at Mar. 31, 2017	$ 9,168	$ 3,365,991		$ (1,891,974)	$ 1,473,186
Ending Balance (in shares) at Mar. 31, 2017	91,685,000

XML 15 R6.htm IDEA: XBRL DOCUMENT

STATEMENT OF CASH FLOWS - USD ($)	9 Months Ended
STATEMENT OF CASH FLOWS - USD ($)	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (887,637)	$ (162,254)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Amortization of prepaid common stock for services		4,911
Amortization of intangible assets	172,033
Share based compensation expense	34,884
Changes in operating assets and liabilities:
Increase in prepaid expenses	6,982	2,000
Receivables
Accounts Payable	209,818
Accrued Payroll	(34,526)	121,106
Net cash used by operating activities	(498,447)	(34,237)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from loan payable
Proceeds from issuance of common stock	409,999
Net cash provided by financing activities	409,999
Net decrease in cash	(88,448)	(34,237)
Cash, beginning of period	123,757	267,481
Cash, end of period	35,309	233,244
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for Income Tax
NON-CASH FINANCING ACTIVITIES
Gain on extinguishment of debt	$ 222,028

XML 16 R7.htm IDEA: XBRL DOCUMENT

Background Information

9 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Background Information

Background Information

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company’s business plan.

XML 17 R8.htm IDEA: XBRL DOCUMENT

Going Concern

9 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Going Concern

Going Concern

XML 18 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

Significant Accounting Policies

Unaudited Interim Financial Statements

Basis of Presentation

Cash

Financial Instruments

The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.

The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Research and Development

Income Taxes

The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at March 31, 2017 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

Earnings (Loss) per Share

Stock-based Compensation

Fair Value Measurements

In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.

Recent accounting pronouncements

XML 19 R10.htm IDEA: XBRL DOCUMENT

Related Party Loan

9 Months Ended

Mar. 31, 2017

Related Party Loan

Related Party Loan

XML 20 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

Office Lease

Employment Agreements

XML 21 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

There is no current or deferred income tax expense or benefit allocated to continuing operations for the nine months ended March 31, 2017.

	March 31, 2017			June 30, 2016
Tax expense (benefit) at U.S. statutory rate	$	(301,797	)	$	(146,889	)
State income tax expense (benefit), net of federal benefit	$	(44,382	)	$	(21,659	)
Effect of non-deductible expenses
Other
Change in valuation allowance	$	346,179		$	168,548
	$	—		$	—

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at March 31, 2017 were as follows:

Deferred tax assets (liability), noncurrent:
Net operating loss	$	346,179
Valuation allowance		(346,179	)
	$	—

Change in valuation allowance:

Balance, June 30, 2016	$	391,848
Increase in valuation allowance		346,179
Balance, March 31, 2017		738,027

As of March 31, 2017, the Company had federal and state net operating loss carry-forwards totaling approximately $1,870,000 which begin expiring in 2022.

XML 22 R13.htm IDEA: XBRL DOCUMENT

Purchase of LAT Pharma

9 Months Ended

Mar. 31, 2017

Business Combinations [Abstract]

Purchase of LAT Pharma

Purchase of LAT Pharma

$	2,303,682	Assets Purchased
	260,193	Liabilities Assumed
	2,043,489	Net Assets Purchased
	2,389,200	Purchase Price
$	345,711	Goodwill from Purchase

Intangible asset detail

$	2,293,770	Intangible Intellectual Property
	345,711	Goodwill
	2,639,481	Intangible Asset from Purchase

Under the 338(h)(10) election, intangibles and goodwill related to the acquisition of LAT Pharma will be fully deductible for tax purposes.

The intangible intellectual property is amortized over 10 years.

	March 2017		December 2015
Intanqible Assets subject to Amortization	$	2,293,770	$
Amortization Expense for 9 Months	$	172,033
Accumulated Amortization as of 3/31/2017	$	280,413

The previous year amortization expense has been amortized for the period from April 11, 2016 to June 30, 2016, The estimated Amortization expense for each of the five succeeding fiscal years will be approximately $229,300 per year.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stockholders' Equity

Stockholders’ Equity

Offering of Stock Options

The following key assumptions were used in the valuation model to value stock option grants for each respective period:

Valuation Date	4/11/2016			4/11/2016			4/11/2016
Stock Price	$	0.06		$	0.06		$	0.06
Exercise Price	$	0.06		$	0.06		$	0.06
Term (expected term for options)		1.00			2.00			3.00
Volatility		56.49	%		58.45	%		97.82	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		0.53	%		0.70	%		0.85	%
Call Option Value ($Millions)	$	0.01		$	0.02		$	0.04
Fair Value	$	13,467		$	19,523		$	36,489

Valuation Date	11/16/2016			12/18/2016			03/14/17
Stock Price	$	0.25		$	0.21		$	0.22
Exercise Price	$	0.25		$	0.21		$	0.22
Term (expected term for options)		2.00			2.00			2.00
Volatility		43.12	%		43.12	%		40.02	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		1.02	%		1.15	%		1.40	%
Call Option Value ($Millions)	$	0.06		$	0.05		$	0.05
Fair Value	$	30,919		$	15,646		$	5,143

Stock option transactions under the Company’s plans for the years ended March 31, 2017 is summarized below:

					Weighted
			Weighed-		Average		Aggregate
			Average		Remaining		Intrinsic
	Shares		Exercise		Contractual		Value
Options	(Thousands)		Price		Term		(Thousands)
Outstanding at June 30, 2016		3,000		0.06		2		—
Granted		—		—		—		—
Exercised		—		—		—		—
Forfeited		—		—		—		—
Outstanding at September 30, 2016		3,000		0.06		2		—
Granted		800		0.24		2		—
Exercised		—		—		—		—
Forfeited		—		—		—		—
Outstanding at December 31, 2016		3,800		0.10		2		—
Granted		100		0.22		2		—
Exercised		—		—		—		—
Forfeited		—		—		—		—
Outstanding at March 31, 2017		3,900		0.10		2		—

Offerings of Common Stock and Warrants

the lowest sale price of the Company’s common stock on the purchase date; or
the arithmetic average of the three (3) lowest closing sale prices for the Company’s common stock during the twelve (12) consecutive trading days ending on the trading day immediately preceding the purchase date.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R15.htm IDEA: XBRL DOCUMENT

Renegotiated Debt

9 Months Ended

Mar. 31, 2017

Notes to Financial Statements

Renegotiated Debt

Renegotiated Debt

XML 25 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2017
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year.
Basis of Presentation	Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash	Cash Cash is maintained at financial institutions and, at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. All of our cash balances were fully insured at March 31, 2017.
Financial Instruments	Financial Instruments The Company’s financial instruments include cash and accounts payable. The carrying amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.
Research and Development	Research and Development Research and development costs are charged to operations when incurred and are included in operating expenses. The Company expensed $375,872 for research and development for the nine months ended March 31, 2017.
Income Taxes	Income Taxes Deferred income tax assets and liabilities arise from temporary differences associated with differences between the financial statements and tax basis of assets and liabilities, as measured by the enacted tax rates, which are expected to be in effect when these differences reverse. Deferred tax assets and liabilities are classified as current or non-current, depending on the classification of the assets or liabilities to which they relate. Deferred tax assets and liabilities not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse. The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10), January 1, 2007. The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there are no unrecognized benefits at March 31, 2017 and since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.
Earnings (Loss) per Share	Earnings (Loss) per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share are computed by dividing net income by the weighted average number of shares of common stock outstanding and dilutive options outstanding during the period. For the three and nine months ended March 31, 2017 and 2016 all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive.
Stock-based Compensation	Stock-based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options, as compensation expense in the financial statements based on their fair values. That expense will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).
Fair Value Measurements	Fair Value Measurements In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2013 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “Fair Value Measurements and Disclosures” (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below: Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2017. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accrued payroll. The carrying amounts of debt converted to long-term notes payable are reported at their original amounts.
Recent accounting pronouncements	Recent accounting pronouncements The Company has reviewed recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC and did not or are not believed by management to have a material impact on the Company’s financial statements.

XML 26 R17.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

9 Months Ended

Mar. 31, 2017

Income Tax Disclosure [Abstract]

Reconciliation of the federal statutory income tax rate to income tax expense expense

	March 31, 2017			June 30, 2016
Tax expense (benefit) at U.S. statutory rate	$	(301,797	)	$	(146,889	)
State income tax expense (benefit), net of federal benefit	$	(44,382	)	$	(21,659	)
Effect of non-deductible expenses
Other
Change in valuation allowance	$	346,179		$	168,548
	$	—		$	—

Schedule of gross amounts of deferred tax assets and deferred tax liabilities

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at March 31, 2017 were as follows:

Deferred tax assets (liability), noncurrent:
Net operating loss	$	346,179
Valuation allowance		(346,179	)
	$	—

Change in valuation allowance:

Balance, June 30, 2016	$	391,848
Increase in valuation allowance		346,179
Balance, March 31, 2017		738,027

XML 27 R18.htm IDEA: XBRL DOCUMENT

Purchase of LAT Pharma (Tables)

9 Months Ended

Mar. 31, 2017

Purchase Of Lat Pharma Tables

Schedule of Assets and Liabilities of LAT Pharma, Inc.

$	2,303,682	Assets Purchased
	260,193	Liabilities Assumed
	2,043,489	Net Assets Purchased
	2,389,200	Purchase Price
$	345,711	Goodwill from Purchase

Intangible asset detail

$	2,293,770	Intangible Intellectual Property
	345,711	Goodwill
	2,639,481	Intangible Asset from Purchase

XML 28 R19.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Mar. 31, 2017

Stockholders Equity Tables

Schedule of Stock option grants for each respective period

The following key assumptions were used in the valuation model to value stock option grants for each respective period:

Valuation Date	4/11/2016			4/11/2016			4/11/2016
Stock Price	$	0.06		$	0.06		$	0.06
Exercise Price	$	0.06		$	0.06		$	0.06
Term (expected term for options)		1.00			2.00			3.00
Volatility		56.49	%		58.45	%		97.82	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		0.53	%		0.70	%		0.85	%
Call Option Value ($Millions)	$	0.01		$	0.02		$	0.04
Fair Value	$	13,467		$	19,523		$	36,489

Valuation Date	11/16/2016			12/18/2016			03/14/17
Stock Price	$	0.25		$	0.21		$	0.22
Exercise Price	$	0.25		$	0.21		$	0.22
Term (expected term for options)		2.00			2.00			2.00
Volatility		43.12	%		43.12	%		40.02	%
Annual Rate of Quarterly Dividends		0.00	%		0.00	%		0.00	%
Discount Rate - Bond Equivalent Yield		1.02	%		1.15	%		1.40	%
Call Option Value ($Millions)	$	0.06		$	0.05		$	0.05
Fair Value	$	30,919		$	15,646		$	5,143

Stock option transactions under the Company’s plans for the years ended March 31, 2017 is summarized below:

			Weighted
		Weighed-	Average	Aggregate
		Average	Remaining	Intrinsic
	Shares	Exercise	Contractual	Value
Options	(Thousands)	Price	Term	(Thousands)
Outstanding at June 30, 2016	3,000	0.06	2	-
Granted	-	-	-	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at September 30, 2016	3,000	0.06	2	-
Granted	800	0.24	2	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at December 31, 2016	3,800	0.10	2	-
Granted	100	0.22	2	-
Exercised	-	-	-	-
Forfeited	-	-	-	-
Outstanding at March 31, 2017	3,900	0.10	2	-

XML 29 R20.htm IDEA: XBRL DOCUMENT

Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Going Concern (Details Narrative) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015
Notes to Financial Statements
Net Loss	$ 178,495	$ 57,810	$ 887,637	$ 162,254	$ 431,923	$ 233,008

XML 30 R21.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended	60 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2019
Notes to Financial Statements
Lease rental	$ 369	$ 4,284	$ 21,420
Lease term (in years)	5 years

XML 31 R22.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	9 Months Ended	12 Months Ended
Income Taxes (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Tax expense (benefit) at U.S. statutory rate	$ (301,797)	$ (146,889)
State income tax expense (benefit), net of federal benefit	(44,382)	(21,659)
Effect of non-deductible expenses
Other
Change in valuation allowance	346,179	168,548
Total

XML 32 R23.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 2) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Deferred tax assets (liability)
Net operating loss		$ 346,179
Valuation allowance	$ (738,027)	(391,848)
Total
Federal and State net operating loss carry-forwards		$ 1,870,000

XML 33 R24.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 3) - USD ($)	9 Months Ended	12 Months Ended
Income Taxes (Details 3) - USD ($)	Mar. 31, 2017	Jun. 30, 2016
Change in valuation allowance:
Beginning Balance	$ 391,848
Increase in valuation allowance	346,179	$ 168,548
Ending Balance	$ 738,027	$ 391,848

XML 34 R25.htm IDEA: XBRL DOCUMENT

Purchase of LAT Pharma (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2016	Apr. 11, 2016
Goodwill	$ 345,711	$ 345,711
Intangible Intellectual Property	$ 2,293,710
LAT Pharma, Inc. [Member]
Assets Purchased			$ 2,303,682
Liabilities Assumed			260,193
Net Assets Purchased			2,043,489
Purchase Price			2,389,200
Goodwill			345,711
Intangible Intellectual Property			2,293,770
Intangible Asset from Purchase			$ 2,639,481

XML 35 R26.htm IDEA: XBRL DOCUMENT

Purchase of LAT Pharma (Details 2) - USD ($)	3 Months Ended		9 Months Ended
Purchase of LAT Pharma (Details 2) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Purchase Of Lat Pharma Details 2
Intangible Assets subject to Amortization	$ 2,293,710		$ 2,293,710
Amortization Expense	57,344		172,033
Accumulated Amortization	$ 280,413		$ 280,413

XML 36 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details) - $ / shares	3 Months Ended
Stockholders' Equity (Details) - $ / shares	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016
Stockholders Equity Details
Option Outstanding at beginning of year	3,800	3,000	3,000
Option Granted	100	800
Option Outstanding at end of year	3,900	3,800	3,000
Outstanding Weighted Average Exercise Price at the beginning	$ .10	$ 0.06	$ 0.06
Weighted Average Exercise Price, Granted	.22	.24
Outstanding Weighted Average Exercise Price at the end	$ .10	$ .10	$ 0.06
Weighted Average Remaining Contractual Term (in years)	2 years	2 years	2 years

XML 37 R28.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 2) - Stock Option [Member] - USD ($)	Mar. 14, 2017	Dec. 18, 2016	Nov. 16, 2016	Apr. 11, 2016
Stock Price	$ 0.22	$ 0.21	$ 0.25	$ 0.06
Exercise Price	$ 0.22	$ 0.21	$ 0.25	$ 0.06
Term	2 years	2 years	2 years	1 year
Volatility	40.02%	43.12%	43.12%	56.49%
Annual Rate of Quarterly Dividends	0.00%	0.00%	0.00%	0.00%
Discount Rate - Bond Equivalent Yield	1.40%	1.15%	1.02%	0.53%
Call Option Value	$ 50,000	$ 50,000	$ 60,000	$ 10,000
Fair Value	$ 5,143	$ 15,646	$ 30,919	$ 13,467
Stock Price				$ 0.06
Exercise Price				$ 0.06
Term				2 years
Volatility				58.45%
Annual Rate of Quarterly Dividends				0.00%
Discount Rate - Bond Equivalent Yield				0.70%
Call Option Value				$ 20,000
Fair Value				$ 19,523
Stock Price				$ 0.06
Exercise Price				$ 0.06
Term				3 years
Volatility				97.82%
Annual Rate of Quarterly Dividends				0.00%
Discount Rate - Bond Equivalent Yield				0.85%
Call Option Value				$ 40,000
Fair Value				$ 36,489

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 57 137 1 false 8 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nanoantibiotics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://nanoantibiotics.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATION Sheet http://nanoantibiotics.com/role/StatementsOfOperation STATEMENTS OF OPERATION Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://nanoantibiotics.com/role/StatementOfStockholdersDeficit STATEMENT OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 00000006 - Statement - STATEMENT OF CASH FLOWS Sheet http://nanoantibiotics.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Going Concern Sheet http://nanoantibiotics.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Related Party Loan Sheet http://nanoantibiotics.com/role/RelatedPartyLoan Related Party Loan Notes 10 false false R11.htm 00000011 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 00000012 - Disclosure - Income Taxes Sheet http://nanoantibiotics.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 00000013 - Disclosure - Purchase of LAT Pharma Sheet http://nanoantibiotics.com/role/PurchaseOfLatPharma Purchase of LAT Pharma Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Equity Sheet http://nanoantibiotics.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 00000015 - Disclosure - Renegotiated Debt Sheet http://nanoantibiotics.com/role/RenegotiatedDebt Renegotiated Debt Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Income Taxes (Tables) Sheet http://nanoantibiotics.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nanoantibiotics.com/role/IncomeTaxes 17 false false R18.htm 00000018 - Disclosure - Purchase of LAT Pharma (Tables) Sheet http://nanoantibiotics.com/role/PurchaseOfLatPharmaTables Purchase of LAT Pharma (Tables) Tables http://nanoantibiotics.com/role/PurchaseOfLatPharma 18 false false R19.htm 00000019 - Disclosure - Stockholders' Equity (Tables) Sheet http://nanoantibiotics.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://nanoantibiotics.com/role/StockholdersEquity 19 false false R20.htm 00000020 - Disclosure - Going Concern (Details Narrative) Sheet http://nanoantibiotics.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://nanoantibiotics.com/role/GoingConcern 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://nanoantibiotics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://nanoantibiotics.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - Income Taxes (Details) Sheet http://nanoantibiotics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://nanoantibiotics.com/role/IncomeTaxesTables 22 false false R23.htm 00000023 - Disclosure - Income Taxes (Details 2) Sheet http://nanoantibiotics.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://nanoantibiotics.com/role/IncomeTaxesTables 23 false false R24.htm 00000024 - Disclosure - Income Taxes (Details 3) Sheet http://nanoantibiotics.com/role/IncomeTaxesDetails3 Income Taxes (Details 3) Details http://nanoantibiotics.com/role/IncomeTaxesTables 24 false false R25.htm 00000025 - Disclosure - Purchase of LAT Pharma (Details) Sheet http://nanoantibiotics.com/role/PurchaseOfLatPharmaDetails Purchase of LAT Pharma (Details) Details http://nanoantibiotics.com/role/PurchaseOfLatPharmaTables 25 false false R26.htm 00000026 - Disclosure - Purchase of LAT Pharma (Details 2) Sheet http://nanoantibiotics.com/role/PurchaseOfLatPharmaDetails2 Purchase of LAT Pharma (Details 2) Details http://nanoantibiotics.com/role/PurchaseOfLatPharmaTables 26 false false R27.htm 00000027 - Disclosure - Stockholders' Equity (Details) Sheet http://nanoantibiotics.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://nanoantibiotics.com/role/StockholdersEquityTables 27 false false R28.htm 00000028 - Disclosure - Stockholders' Equity (Details 2) Sheet http://nanoantibiotics.com/role/StockholdersEquityDetails2 Stockholders' Equity (Details 2) Details http://nanoantibiotics.com/role/StockholdersEquityTables 28 false false All Reports Book All Reports bivi-20170331.xml bivi-20170331.xsd bivi-20170331_cal.xml bivi-20170331_def.xml bivi-20170331_lab.xml bivi-20170331_pre.xml true true ZIP 44 0001520138-17-000167-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-17-000167-xbrl.zip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

/s/ Jonathan Adams

Jonathan Adams

Chief Executive Officer, Chief Financial Officer, Principal Executive Officer and Principal Financial and Accounting Officer, Treasurer and Chairman of the Board

March 8, 2017